Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
BeovuⓇ - Anti-VEGF
Appendix
Innovation: Clinical trials
Respiratory & Allergy
Oncology: Solid Tumors
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04005352 TALON (CRTH258A2303)
Neovascular Age-related Macular Degeneration (nAMD)
Phase 3B
739
Average change in Best-corrected visual acuity
Distribution of the last interval with no disease activity (in a Treat-to-Control
regimen)
Arm 1: Brolucizumab 6 mg intravitreal injection
Arm 2: Aflibercept 2 mg intravitreal injection
Patients with Neovascular Age-related Macular Degeneration (nAMD) who have not
previously received anti-VEGF (vascular endothelial growth factor) treatment
Target Patients
Read-out Milestone(s)
2022
Publication
TBD
79 Investor Relations | Q1 2022 Results
References
Abbreviations
Hematology
Biosimilars
Global Health
1 NOVARTIS | Reimagining MedicineView entire presentation